These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 8789222)

  • 41. Adverse skin reactions to low molecular weight heparins: frequency, management and prevention.
    Wütschert R; Piletta P; Bounameaux H
    Drug Saf; 1999 Jun; 20(6):515-25. PubMed ID: 10392668
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Delayed-type hypersensitivity to low molecular weight heparins and heparinoids: cross-reactivity does not depend on molecular weight. Commentary.
    Gómez-Outes A; Gómez de la Bárcena C; Martínez-González J
    Br J Dermatol; 2008 Apr; 158(4):869-70. PubMed ID: 18284394
    [No Abstract]   [Full Text] [Related]  

  • 43. Delayed-type skin reaction to the heparin-alternative danaparoid.
    Szolar-Platzer C; Aberer W; Kränke B
    J Am Acad Dermatol; 2000 Nov; 43(5 Pt 2):920-2. PubMed ID: 11044823
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Eczematous plaques related to unfractionated and low-molecular-weight heparins: cross-reaction with danaparoid but not with desirudin.
    Martin L; Machet L; Gironet N; Pouplard C; Gruel Y; Vaillant L
    Contact Dermatitis; 2000 May; 42(5):295-6. PubMed ID: 10789857
    [No Abstract]   [Full Text] [Related]  

  • 45. Fondaparinux: a suitable alternative in cases of delayed-type allergy to heparins and semisynthetic heparinoids? A study of 7 cases.
    Jappe U; Juschka U; Kuner N; Hausen BM; Krohn K
    Contact Dermatitis; 2004 Aug; 51(2):67-72. PubMed ID: 15373846
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The influence of heparin's molecular weight and the incidence of delayed type hypersensitivity reactions revisited; in response to Grims et al., Br J Dermatol 2007; 157:514-17.
    Ludwig RJ; Schindewolf M; Lindhoff-Last E; Boehncke WH
    Br J Dermatol; 2008 Apr; 158(4):849-51. PubMed ID: 18205866
    [No Abstract]   [Full Text] [Related]  

  • 47. [Therapy of venous thromboembolism with low-molecular-weight heparins].
    Haas S; Haas P; Creutzig A
    Vasa; 2000 Feb; 29(1):5-10. PubMed ID: 10731882
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Treatment and prophylaxis of deep venous thrombosis with low molecular weight heparins (meta-analysis of clinical trials)].
    Valiukiene L; Naudziūnas A; Unikauskas A
    Medicina (Kaunas); 2003; 39(4):352-8. PubMed ID: 12738903
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Low-molecular-weight heparin-induced bullous haemorrhagic dermatosis associated with cell-mediated hypersensitivity].
    Thuillier D; Chaby G; Dadban A; Dascotte E; Miquel-Christophe O; Andrejak M; Chatelain D; Lok C
    Ann Dermatol Venereol; 2009 Oct; 136(10):705-8. PubMed ID: 19801254
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Skin necrosis at the injection site induced by low-molecular-weight heparin: case report and review.
    Santamaría A; Romaní J; Souto JC; López A; Mateo J; Fontcuberta J
    Dermatology; 1998; 196(2):264-5. PubMed ID: 9568422
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Delayed hypersensitivity to enoxaparin.
    Cabañas R; Caballero MT; López-Serrano MC; Díaz R; Contreras J; Barranco P; Moreno-Ancillo A
    J Investig Allergol Clin Immunol; 1998; 8(6):383-4. PubMed ID: 10028487
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Hypersensitivity reactions to low molecular weight heparins: different patterns of cross-reactivity in 3 patients.
    Juricic Nahal D; Cegec I; Erdeljic Turk V; Makar Ausperger K; Kraljickovic I; Simic I
    Can J Physiol Pharmacol; 2018 Apr; 96(4):428-432. PubMed ID: 28977756
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Delayed allergic skin reactions due to subcutaneous heparin-calcium, enoxaparin-sodium, pentosan polysulfate and acute skin lesions from systemic sodium-heparin.
    Koch P; Hindi S; Landwehr D
    Contact Dermatitis; 1996 Feb; 34(2):156-8. PubMed ID: 8681559
    [No Abstract]   [Full Text] [Related]  

  • 54. Low-molecular-weight heparin compared with intravenous unfractionated heparin for treatment of pulmonary embolism: a meta-analysis of randomized, controlled trials.
    Quinlan DJ; McQuillan A; Eikelboom JW
    Ann Intern Med; 2004 Feb; 140(3):175-83. PubMed ID: 14757615
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Low doses of low molecular weight heparin in vivo do not inhibit delayed-type hypersensitivity.
    Zachariae CO; Larsen CG; Thomsen PD; Nowak J; Zachariae R; Menné T
    Acta Derm Venereol; 1997 Nov; 77(6):495-6. PubMed ID: 9395002
    [No Abstract]   [Full Text] [Related]  

  • 56. Low-molecular-weight heparins compared with unfractionated heparin for treatment of acute deep venous thrombosis. A meta-analysis of randomized, controlled trials.
    Gould MK; Dembitzer AD; Doyle RL; Hastie TJ; Garber AM
    Ann Intern Med; 1999 May; 130(10):800-9. PubMed ID: 10366369
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Comparison of low molecular weight heparins and unfractionated heparin after successive subcutaneous administration. A randomized controlled study in healthy volunteers.
    Pindur G; Heiden M; Köhler M
    Arzneimittelforschung; 1993 May; 43(5):542-7. PubMed ID: 8392345
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Fixed-dose, body weight-independent subcutaneous low molecular weight heparin Certoparin compared with adjusted-dose intravenous unfractionated heparin in patients with proximal deep venous thrombosis.
    Riess H; Koppenhagen K; Tolle A; Kemkes-Matthes B; Gräve M; Patek F; Drexler M; Siemens HJ; Harenberg J; Weidinger G; Brom J; Haas S;
    Thromb Haemost; 2003 Aug; 90(2):252-9. PubMed ID: 12888872
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Effects of a low-molecular-weight heparin on thrombus regression and recurrent thromboembolism in patients with deep-vein thrombosis.
    Breddin HK; Hach-Wunderle V; Nakov R; Kakkar VV;
    N Engl J Med; 2001 Mar; 344(9):626-31. PubMed ID: 11228276
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Subcutaneous enoxaparin once or twice daily compared with intravenous unfractionated heparin for treatment of venous thromboembolic disease.
    Merli G; Spiro TE; Olsson CG; Abildgaard U; Davidson BL; Eldor A; Elias D; Grigg A; Musset D; Rodgers GM; Trowbridge AA; Yusen RD; Zawilska K;
    Ann Intern Med; 2001 Feb; 134(3):191-202. PubMed ID: 11177331
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.